USFDA22 Apr 2026, 11:50 am
Supriya Lifescience Receives EIR from USFDA with VAI Status
AI Summary
Supriya Lifescience Ltd. announced the successful completion of a USFDA inspection at its Lote, Maharashtra manufacturing facility, conducted from February 2 to February 6, 2026. The inspection concluded with a Form 483 containing one minor observation, which the company addressed adequately. The company received an Establishment Inspection Report (EIR) indicating "Voluntary Action Indicated (VAI)", signifying a successful completion of the inspection. The company reaffirms its commitment to maintaining cGMP compliance across all facilities.
Key Highlights
- USFDA inspected Supriya Lifescience's Lote facility in February 2026.
- The inspection concluded with one minor observation in Form 483.
- The company received an EIR with a VAI status, indicating successful inspection completion.
- Supriya Lifescience is committed to cGMP compliance.